通过两种不同的α2-上腺素受体亚型的反抑制甲醇胺释放,可以防止心力衰竭的进展
Marc Brede1, Frank Wiesmann, Roland Jahns
1Institut für Pharmakologie und Toxikologie, Universität Würzburg, Germany.
Circulation
|November 6, 2002
概括
阿尔法2A和阿尔法2C上腺受体对于预防小鼠和人类心力衰竭进展至关重要. 这些受体中的遗传变异加剧了心力衰竭的结果,这表明了新的治疗点.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 升的诺亚上腺素与慢性心力衰竭的死亡率增加有关.
- 阿尔法2-上腺受体调节北上腺素的释放,可能会影响心力衰竭的进展.
研究的目的:
- 调查控制心力衰竭中上腺素释放的α2-上腺受体亚型.
- 评估alpha2-adrenoceptor亚型在应对心脏压力过载时的作用.
- 确定对人类心力衰竭患者遗传α2-上腺受体变异的影响.
主要方法:
- 利用基因向小鼠缺乏特定的α2-上腺受体亚型 (α2-KO).
- 通过横向大动脉收缩诱导的慢性左心室压力过载.
- 在KO和野生型小鼠中分析了存活率,心脏缩,纤维化和循环中的甲醇胺.
- 评估了人类心力衰竭患者的临床状况和心脏功能,这些患者具有遗传alpha2C-adrenoceptor变异.
主要成果:
- 与对照组相比,alpha2A-KO和alpha2C-KO小鼠的生存率显著降低.
- 阿尔法2A和阿尔法2C-KO小鼠表现出恶化的心力衰竭,包括左心室缩,纤维化和升高的类甲醇胺.
- 患有功能障碍的α2C-腺受体变异的人类心力衰竭患者表现出较差的临床状态和心脏功能降低.
结论:
- 阿尔法2A和阿尔法2C上腺受体在预防心力衰竭进展方面发挥着至关重要的作用.
- 阿尔法2-上腺受体的遗传变异与心力衰竭的更糟糕结果有关.
- 准α2-上腺受体变体和开发亚型选择性药物为心力衰竭提供了新的治疗策略.
相关概念视频
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...